Factors influencing choice of chemotherapy in metastatic colorectal cancer (mCRC)

References

• MalvezziMArféABertuccioPLeviFLa VecchiaCNegriEEuropean cancer mortality predictions for the year 2011Ann Oncol20112294795621303801
   PubMed Web of Science ®Google Scholar
• SchmollHJVan CutsemESteinAESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision makingAnn Oncol2012232479251623012255
   PubMed Web of Science ®Google Scholar
• FolprechtGGrotheyAAlbertsSRaabHRKöhneCHNeoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection ratesAnn Oncol2005161311131915870084
   PubMed Web of Science ®Google Scholar
• Altendorf-HofmannAScheeleJA critical review of the major indicators of prognosis after resection of hepatic metastases from colorectal carcinomaSurg Oncol Clin N Am20031216519212735137
   PubMedGoogle Scholar
• NordlingerBVan CutsemEGruenbergerTEuropean Colorectal Metastases Treatment GroupSixth International Colorectal Liver Metastases WorkshopCombination of surgery and chemotherapy and the role of targeted agents in the treatment of patients with colorectal liver metastases: recommendations from an expert panelAnn Oncol200920698599219153115
   PubMed Web of Science ®Google Scholar
• NordlingerBSorbyeHGlimeliusBEORTC Gastro-Intestinal Tract Cancer GroupCancer Research UKArbeitsgruppe Lebermetastasen und-tumoren in der Chirurgischen Arbeitsgemeinschaft Onkologie (ALM-CAO)Australasian Gastro-Intestinal Trials Group (AGITG)Fédération Francophone de Cancérologie Digestive (FFCD)Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomized controlled trialLancet20083711007101618358928
   PubMed Web of Science ®Google Scholar
• CilibertoDPratiURovedaLRole of systemic chemotherapy in the management of resected or resectable colorectal liver metastases: a systematic review and meta-analysis of randomized controlled trialsOncol Rep2012271849185622446591
   PubMed Web of Science ®Google Scholar
• PrimroseJNFalkSFinch-JonesMA randomized clinical trial of chemotherapy compared to chemotherapy in combination with cetuximab in k-RAS wild-type patients with operable metastases from colorectal cancer: the new EPOC studyProceedings of the 13th ASCO annual meetingMay 31–June 4, 2013Chicago, IL
   Google Scholar
  J Clin Oncol201331Supplabstract 3504
   Google Scholar
• BilchikAJPostonGAdamRChotiMAPrognostic variables for resection of colorectal cancer hepatic metastases: an evolving paradigmJ Clin Oncol2008265320532118936470
   PubMed Web of Science ®Google Scholar
• LimmerSUngerLOptimal management of pulmonary metastases from colorectal cancerExpert Rev Anticancer Ther201111101567157521999130
   PubMed Web of Science ®Google Scholar
• DelaunoitTAlbertsSRSargentDJChemotherapy permits resection of metastatic colorectal cancer: experience from Intergroup N9741Ann Oncol20051642542915677624
   PubMed Web of Science ®Google Scholar
• PozzoCBassoMCassanoANeoadjuvant treatment of unresectable liver disease with irinotecan and 5-fluorouracil plus folinic acid in colorectal cancer patientsAnn Oncol20041593393915151951
   PubMed Web of Science ®Google Scholar
• AlbertsSRHorvathWLSternfeldWCOxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II studyJ Clin Oncol2005239243924916230673
   PubMed Web of Science ®Google Scholar
• FolprechtGGruenbergerTBechsteinWOTumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trialLancet Oncol201011384719942479
   PubMed Web of Science ®Google Scholar
• PetrelliFBarniSResectability and outcome with anti-EGFR agents in patients with KRAS wild-type colorectal liver-limited metastases: a meta-analysisInt J Colorectal Dis201227997100422358385
   PubMed Web of Science ®Google Scholar
• HurwitzHFehrenbacherLNovotnyWBevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancerN Engl J Med20043502335234215175435
   PubMed Web of Science ®Google Scholar
• SaltzLBClarkeSDiaz-RubioEBevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III studyJ Clin Oncol2008262013201918421054
   PubMed Web of Science ®Google Scholar
• MasiGLoupakisFSalvatoreLBevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trialLancet Oncol20101184585220702138
   PubMed Web of Science ®Google Scholar
• MasiGVasileELoupakisFRandomized trial of two induction chemotherapy regimens in metastatic colorectal cancer: an updated analysisJ Natl Cancer Inst2011103213021123833
   PubMed Web of Science ®Google Scholar
• FalconeACremoliniCMasiGFOLFOXIRI/bevacizumab (bev) versus FOLFIRI/bev as first-line treatment in unresectable metastatic colorectal cancer (mCRC) patients (pts): Results of the phase III TRIBE trial by GONO groupProceedings of the 13th ASCO annual meetingMay 31–June 4, 2013Chicago, IL
   Google Scholar
  J Clin Oncol201331Supplabstract 3505
   Google Scholar
• [No authors listed]Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. Advanced Colorectal Cancer Meta-Analysis ProjectJ Clin Oncol19921068969031534121
   PubMed Web of Science ®Google Scholar
• TournigandCAndréTAchilleEFOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR studyJ Clin Oncol20042222923714657227
   PubMed Web of Science ®Google Scholar
• ColucciGGebbiaVPaolettiGGruppo Oncologico Dell’Italia MeridionalePhase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell’Italia MeridionaleJ Clin Oncol2005234866487515939922
   PubMed Web of Science ®Google Scholar
• Diaz-RubioETaberneroJGomez-EspanaAPhase III study of capecitabine plus oxliplatino versus continuous-infusion fluouracil plus oxaliplatin as first line therapy in metastatic colorectal cancerJ Clin Oncol200725274224423017548839
   PubMed Web of Science ®Google Scholar
• KöhneCHDe GreveJHartmannJTIrinotecan combined with infusional 5-fluorouracil/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer. EORTC study 40015Ann Oncol20081992092618065406
   PubMed Web of Science ®Google Scholar
• Van CutsemEKöhneCHLángICetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation statusJ Clin Oncol2011292011201921502544
   PubMed Web of Science ®Google Scholar
• AmadoRGWolfMPeetersMWild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancerJ Clin Oncol200826101626163418316791
   PubMed Web of Science ®Google Scholar
• OlinerKSDouillardJYSienaSAnalysis of KRAS/NRAS and BRAF mutations in the phase III PRIME study of panitumumab (pmab) plus FOLFOX versus FOLFOX as first-line treatment (tx) for metastatic colorectal cancer (mCRC)Proceedings of the 13th ASCO annual meetingMay 31–June 4, 2013Chicago, IL
   Google Scholar
  J Clin Oncol201331Supplabstract 3511
   Google Scholar
• DouillardJYSienaSCassidyJRandomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME studyJ Clin Oncol2010284697470520921465
   PubMed Web of Science ®Google Scholar
• BokemeyerCBondarenkoIMakhsonAFluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancerJ Clin Oncol20092766367119114683
   PubMed Web of Science ®Google Scholar
• HeinemannVvon WeikersthalLFDeckerTRandomized comparison of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment of KRAS wild-type metastatic colorectal cancer: German AIO study KRK-0306 (FIRE-3)Proceedings of the 13th ASCO annual meetingMay 31–June 4, 2013Chicago, IL
   Google Scholar
  J Clin Oncol201331Supplabstract LBA3506
   Google Scholar
• Cancer and Leukemia Group BCetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer Available from: http://clinicaltrials.gov/show/NCT00265850. ClinicalTrials.gov Identifier: NCT00265850Accessed October 24, 2013
   Google Scholar
• CunninghamDLangILorussoVBevacizumab (bev) in combination with capecitabine (cape) for the first-line treatment of elderly patients with metastatic colorectal cancer (mCRC): results of a randomized international phase III trial (AVEX)Proceedings of the Gastrointestinal Cancer Symposium ASCO GIJanuary 24–26, 2013San Francisco, CA
   Google Scholar
  J Clin Oncol201330Suppl 34abstract 337
   Google Scholar
• TournigandCCervantesAFigerAOPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer – a GERCOR studyJ Clin Oncol20062439440016421419
   PubMed Web of Science ®Google Scholar
• GrotheyAHartLRowlandKIntermittent oxaliplatin administration improves time-to-treatment failure in metastatic colorectal cancer: final results of the phase III of the CONCEPT TrialJ Clin Oncol200826Suppl4010
   Google Scholar
• TveitKGurenTGlimeliusBPhase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII studyJ Clin Oncol2012301755176222473155
   PubMed Web of Science ®Google Scholar
• Díaz-RubioEGómez-EspañaAMassutíBSpanish Cooperative Group for the Treatment of Digestive TumorsFirst-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: the phase III MACRO TTD studyOncologist2012171152522234633
   PubMed Web of Science ®Google Scholar
• KoopmanMSimkensLKJTen TijeAJMaintenance treatment with capecitabine and bevacizumab versus observation after induction treatment with chemotherapy and bevacizumab in metastatic colorectal cancer (mCRC): the phase III CAIRO3 study of the Dutch Colorectal Cancer Group (DCCG)Proceedings of the 13th ASCO annual meetingMay 31–June 4, 2013Chicago, IL
   Google Scholar
  J Clin Oncol201331Supplabstract 3502
   Google Scholar
• KoeberleDBetticherDCVon MoosRBevacizumab continuation versus no continuation after first-line chemo-bevacizumab therapy in patients with metastatic colorectal cancer: a randomized phase III noninferiority trial (SAKK 41/06)Proceedings of the 13th ASCO annual meetingMay 31–June 4, 2013Chicago, IL
   Google Scholar
  J Clin Oncol201331Supplabstract 3503
   Google Scholar
• AIO-Studien-gGmbHOptimal Maintenance Therapy With Bevacizumab After Induction in Metastatic Colorectal Cancer (CRC) Available from: http://clinicaltrials.gov/show/NCT00973609. ClinicalTrials.gov Identifier: NCT00973609Accessed October 24, 2013
   Google Scholar
• TournigandCSamsonBScheithauerWBevacizumab (Bev) with or without erlotinib as maintenance therapy, following induction first-line chemotherapy plus Bev, in patients (pts) with metastatic colorectal cancer (mCRC): efficacy and safety results of the International GERCOR DREAM phase III trialProceedings of the 12th ASCO annual meetingChicago1–5, June 2012
   Google Scholar
  J Clin Oncol201230Suppl 18abstract LBA3500
   Google Scholar
• ChibaudelBMaindrault-GoebelFLledoGCan chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 StudyJ Clin Oncol2009275727573319786657
   PubMed Web of Science ®Google Scholar
• MaughanTSAdamsRASmithCGAddition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trialLancet20113772103211421641636
   PubMed Web of Science ®Google Scholar
• PeetersMPriceTJCervantesARandomized phase III study of panitumumab with fluorouracil, leucovorin and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancerJ Clin Oncol2010284706471320921462
   PubMed Web of Science ®Google Scholar
• SobreroAFMaurelJFehrenbacherLEPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancerJ Clin Oncol2008262311231918390971
   PubMed Web of Science ®Google Scholar
• GiantonioBJCatalanoPJMeropolNJEastern Cooperative Oncology Group Study E3200Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200J Clin Oncol2009251539154417442997
   PubMed Web of Science ®Google Scholar
• BennounaJSastreJArnoldContinuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trialLancet Oncol2013141293723168366
   PubMed Web of Science ®Google Scholar
• Van CutsemETaberneroJLakomyRAddition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase iii randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimenJ Clin Oncol2012303499350622949147
   PubMed Web of Science ®Google Scholar
• CunninghamDHumbletYSienaSCetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancerN Engl J Med200435133734515269313
   PubMed Web of Science ®Google Scholar
• Van CutsemEPeetersMSienaSOpen-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancerJ Clin Oncol2007251658166417470858
   PubMed Web of Science ®Google Scholar
• GrotheyAVan CutsemESobreroACORRECT Study GroupRegorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trialLancet2013381986330331223177514
   PubMed Web of Science ®Google Scholar